Ignite Creation Date:
2025-12-24 @ 6:41 PM
Ignite Modification Date:
2025-12-25 @ 4:12 PM
Study NCT ID:
NCT02612857
Status:
COMPLETED
Last Update Posted:
2019-10-10
First Post:
2015-11-18
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Trial of IMO-8400 in Adult Patients With Dermatomyositis
Sponsor:
Idera Pharmaceuticals, Inc.
Organization:
Study Overview
Official Title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis
Status:
COMPLETED
Status Verified Date:
2019-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
8400-211
Brief Summary:
The purpose of this study is to determine how safe and effective IMO-8400 is in adults with dermatomyositis.
Detailed Description:
This study will evaluate the safety and efficacy of IMO-8400 in adults with active dermatomyositis (DM).
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: